Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study

Abstract Aims Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a therapeutic target for reducing plasma low‐density lipoprotein cholesterol. Beyond lipid control, recent findings suggest a deleterious effect of this protein in the pathogenesis of postmyocardial infarction left ve...

Full description

Bibliographic Details
Main Authors: Gema Miñana, Julio Núñez, Antoni Bayés‐Genís, Elena Revuelta‐López, César Ríos‐Navarro, Eduardo Núñez, Francisco J. Chorro, Maria Pilar López‐Lereu, Jose Vicente Monmeneu, Josep Lupón, Juan Sanchis, Vicent Bodí
Format: Article
Language:English
Published: Wiley 2020-02-01
Series:ESC Heart Failure
Subjects:
PCSK9
Left ventricular ejection fraction
Cardiac magnetic resonance
ST‐segment elevation myocardial infarction
Online Access:https://doi.org/10.1002/ehf2.12533

Internet

https://doi.org/10.1002/ehf2.12533

Similar Items